Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corp, recently executed a series of stock transactions that highlight her active management of personal holdings in the company. On October 15, 2026, Rothblatt exercised stock options and sold shares, actions that are significant for both her and the company.
United Therapeutics, incorporated in Delaware, is a prominent player in the pharmaceutical industry, focusing on innovative therapies for patients with chronic and life-threatening conditions. The company’s operations are classified under the Pharmaceutical Preparations sector.
According to the recent SEC filing, Rothblatt exercised options for 9,500 shares of common stock at a price of $117.76 each. Additionally, she sold a total of 4,000 shares across several transactions, with prices ranging from approximately $540 to $551 per share. Following these transactions, Rothblatt retains ownership of 333,943 shares, held in trust.
This series of transactions is part of a pre-arranged 10b5-1 trading plan that Rothblatt established on November 7, 2025. Such plans allow executives to manage their stock transactions in a manner that complies with insider trading regulations, thus providing a level of transparency and predictability.
The impact of Rothblatt's actions may resonate beyond her personal holdings. As a leader in the pharmaceutical sector, her decisions can influence perceptions of executive compensation and stock management practices within the industry. Other executives and companies may take cues from Rothblatt’s strategic approach to stock options and share sales.
Looking ahead, it remains to be seen if further filings will detail additional transactions or changes in Rothblatt’s holdings. The filing does not specify what happens next, leaving room for speculation about future stock movements or company strategies.